Irbesartan/Hydrochlorothiazide Eg (Hydrochlorothiazide, Irbesartan)

• Irbesartan/Hydrochlorothiazide Eg is indicated for hypertension, a condition characterized by chronically elevated arterial pressure.
• Hypertension: lowers systolic and diastolic blood pressure, helping to reduce the risk of cardiovascular events.

• Irbesartan blocks the binding of angiotensin II to AT1 receptors, producing vasodilation and decreasing aldosterone‑mediated sodium retention. Hydrochlorothiazide inhibits NaCl reabsorption in the distal convoluted tubule, increasing urinary excretion of sodium and water, which reduces plasma volume. The combined actions result in a synergistic reduction of systemic vascular resistance and blood volume, thereby lowering arterial pressure.

Adverse reactions to Irbesartan/Hydrochlorothiazide Eg may vary in frequency and severity.

Common Side Effects

• Dizziness or light‑headedness
• Headache
• Increased urinary frequency
• Electrolyte disturbances such as low potassium
• Mild gastrointestinal discomfort

Serious or Rare Side Effects

• Angioedema (swelling of face, lips, tongue)
• Severe dehydration or electrolyte imbalance
• Acute kidney injury or sudden rise in serum creatinine
• Severe allergic reactions (rash, hives, anaphylaxis)
• Hyperuricemia leading to gout attacks

When prescribing Irbesartan/Hydrochlorothiazide Eg, clinicians should consider several safety measures.

• Blood pressure monitoring: check regularly to ensure therapeutic response.
• Electrolyte assessment: monitor serum potassium and sodium levels, especially in patients on other diuretics.
• Renal function: evaluate creatinine and eGFR before initiation and during therapy.
• Diabetes mellitus: use caution as thiazide component may affect glucose control.
• Pregnancy: avoid unless clearly indicated, as safety data are limited.
• Store at ambient temperature: keep in the original container, protect from moisture and light.

Irbesartan/Hydrochlorothiazide Eg can interact with several medicines; awareness of the interaction potential helps maintain safety.

Major Interactions (Avoid)

• Potassium‑sparing diuretics: risk of hyperkalemia.
• ACE inhibitors or ARBs combined with aliskiren in diabetic patients: increased adverse events.
• Lithium: thiazide component may raise lithium levels, risking toxicity.
• NSAIDs: may blunt antihypertensive effect and affect renal function.
• Cyclosporine: combined use may increase nephrotoxicity.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: additive blood‑pressure lowering may cause excessive hypotension.
• Corticosteroids: may enhance potassium loss.
• Antidiabetic agents: thiazide may elevate blood glucose, requiring dose adjustment.